for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Johnson & Johnson

JNJ

Latest Trade

141.38USD

Change

0.04(+0.03%)

Volume

4,257,231

Today's Range

140.31

 - 

141.80

52 Week Range

121.00

 - 

148.59

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
141.34
Open
141.10
Volume
4,257,231
3M AVG Volume
154.18
Today's High
141.80
Today's Low
140.31
52 Week High
148.59
52 Week Low
121.00
Shares Out (MIL)
2,631.87
Market Cap (MIL)
371,988.80
Forward P/E
16.30
Dividend (Yield %)
2.69

Next Event

Q4 2019 Johnson & Johnson Earnings Call

Latest Developments

More

Darzalex Regimen Shows Significant Increase In Progression-Free Survival In Treatment Of Patients With Relapsed/Refractory Multiple Myeloma

HitGen Collaborates With Janssen Biotech To Create New DNA-Encoded Libraries

XBiotech Announces Agreement To Sell True Human Antibody Bermekimab Targeting Il-1A To Janssen

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

Industry

Biotechnology & Drugs

Contact Info

1 Johnson And Johnson Plz

+1.732.5242455

https://www.jnj.com/

Executive Leadership

Alex Gorsky

Chairman of the Board, Chief Executive Officer

Paulus A. Stoffels

Vice Chairman- Executive Committee, Chief Scientific Officer

Joaquin Boix Duato

Vice Chairman - Executive Committee

Joseph J. Wolk

Chief Financial Officer, Executive Vice President

Peter M. Fasolo

Chief Human Resource Officer, Executive Vice President

Key Stats

2.16 mean rating - 19 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

71.9K

2017

76.5K

2018

81.6K

2019(E)

82.1K
EPS (USD)

2016

6.730

2017

7.300

2018

8.180

2019(E)

8.669
Price To Earnings (TTM)
26.95
Price To Sales (TTM)
4.55
Price To Book (MRQ)
6.39
Price To Cash Flow (TTM)
17.65
Total Debt To Equity (MRQ)
49.34
LT Debt To Equity (MRQ)
46.24
Return on Investment (TTM)
11.38
Return on Equity (TTM)
9.09

Latest News

Latest News

J&J CEO spurns U.S. congressional hearing on carcinogens in talc products

Johnson & Johnson <JNJ.N> Chief Executive Officer Alex Gorsky has declined to appear at a U.S. congressional hearing set for Tuesday on the safety of the company's Baby Powder and other talc-based cosmetics.

J&J CEO Gorsky spurns U.S. congressional hearing on carcinogens in talc products

Johnson & Johnson Chief Executive Officer Alex Gorsky has declined to appear at a U.S. congressional hearing set for Tuesday on the safety of the company's Baby Powder and other talc-based cosmetics.

BRIEF-Argenx Receives First Milestone Payment Under Janssen Collaboration

* ARGENX ANNOUNCED ON SATURDAY RECEIPT OF FIRST MILESTONE PAYMENT UNDER JANSSEN COLLABORATION AND PROVIDES DATA UPDATE FROM PHASE 1 DOSE ESCALATION TRIAL OF CUSATUZUMAB IN ACUTE MYELOID LEUKEMIA AT ASH ANNUAL MEETING

FDA approves Amgen's biosimilar to J&J's rheumatoid arthritis drug

The U.S. Food and Drug Administration on Friday approved Amgen Inc's biosimilar copy of Johnson & Johnson's blockbuster rheumatoid arthritis drug, Remicade, according to the regulator's website.

FDA approves Amgen's biosimilar to J&J's rheumatoid arthritis drug

The U.S. Food and Drug Administration on Friday approved Amgen Inc's biosimilar copy of Johnson & Johnson's blockbuster rheumatoid arthritis drug, Remicade, according to the regulator's website.

Johnson & Johnson says new tests show no asbestos in Johnson's Baby Powder

Johnson & Johnson said on Tuesday that recent tests showed that Johnson's Baby Powder was free of asbestos, after U.S. Food and Drug Administration investigations reported trace amounts of the material in the product earlier this year.

U.S. regions hard hit by opioids to ditch class action, pursue own lawsuits

Local governments in regions hard hit by the U.S. opioid epidemic have opted out of massive litigation taking aim at the drug industry over the crisis, potentially weakening a novel legal mechanism created to help settle thousands of lawsuits.

Johnson & Johnson confirms no asbestos in Johnson's Baby Powder

Johnson & Johnson said on Tuesday that more tests showed that Johnson's Baby Powder was free of asbestos after U.S. Food and Drug Administration investigations had found trace amounts of the material.

Imerys considers sale of North American talc business: Bloomberg

French group Imerys SA <IMTP.PA> is exploring options for its North America talc unit, which filed for bankruptcy after being drawn into cancer lawsuits connected to Johnson & Johnson's <JNJ.N> baby powder, Bloomberg reported on Wednesday, citing people with knowledge of...

J&J loses bid to overturn $76.6 million Risperdal injury award

A Pennsylvania appeals court on Tuesday upheld a $76.6 million jury award to a man who claimed he developed breasts after using Johnson & Johnson's antipsychotic drug Risperdal as a child and cleared the way for him to seek punitive damages.

Oklahoma to seek billions more from J&J over opioid crisis on appeal

Oklahoma's attorney general on Thursday announced that he would appeal a judge's decision to limit the amount Johnson & Johnson must pay for fueling the opioid epidemic through the deceptive marketing of painkillers to $465 million.

Johnson & Johnson loses pelvic mesh class action in Australia

More than 1,350 Australian women won a seven-year-old class action lawsuit on Thursday against Johnson & Johnson (J&J) for misleading patients and surgeons about the risks of the pharmaceutical giant's pelvic mesh implants.

Pennsylvania top court rejects J&J bid to toss thousands of Risperdal cases

Pennsylvania's top court on Wednesday overturned a ruling that Johnson & Johnson hoped would have resulted in the dismissal of lawsuits by thousands of men who claim its anti-psychotic drug Risperdal caused them to develop excessive breast tissue.

Oklahoma judge reduces Johnson & Johnson opioid payout to $465 million

An Oklahoma judge on Friday said Johnson & Johnson must pay that state $465 million for fueling the opioid epidemic through the deceptive marketing of painkillers, down from his original award of $572 million.

Oklahoma judge reduces Johnson & Johnson payout in opioid case to $465 million

An Oklahoma judge on Friday said Johnson & Johnson only needs to pay $465 million of the $572 million he previously concluded it owed the state for fueling the opioid epidemic through deceptive painkiller marketing.

9th Circuit questions whistleblower swap in lawsuit against J&J

A federal appeals court suggested on Thursday that a faulty notice of appeal may leave it without jurisdiction to consider whether to revive a whistleblower lawsuit accusing Johnson & Johnson of improperly marketing a hepatitis C drug.

Law firm behind J&J mesh verdicts loses bid to avoid fee assessment

The law firm Kline & Specter has lost a bid to avoid having $17.34 million of $346.8 million in pelvic mesh injury verdicts it won for plaintiffs in cases against Johnson & Johnson go to a fund that compensates the lead attorneys in multidistrict federal litigation over...

Johnson & Johnson files for European approval of Ebola vaccine

Johnson & Johnson <JNJ.N> said on Thursday it had filed for an approval from European regulators for its two-dose experimental vaccine to protect against Ebola, less than a month after the agency recommended approval of Merck & Co Inc's <MRK.N> vaccine.

Johnson & Johnson files for European approval of Ebola vaccine

Johnson & Johnson said on Thursday it had filed for European approval for its experimental vaccine regimen to protect against a strain of Ebola virus that most commonly causes outbreaks of the deadly disease.

Exclusive: J&J's own expert, working for FDA, found asbestos in Baby Powder

Ever since Johnson & Johnson disclosed this month that a government test had turned up asbestos in its Baby Powder, the company has attacked the validity of the result.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up